5/9/2025

NEW YORK, May 9, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. of a class action securities lawsuit. ...

Source: Finnhub

5/8/2025

The Hartford Healthcare Fund (I Share) underperformed the S&P Composite 1500 Health Care Index during the quarter. Read more here.

Source: SeekingAlpha

5/8/2025

Ironwood incurs a wider-than-expected loss in the first quarter of 2025. Revenues plunge year over year. Shares fall.

Source: Yahoo

5/8/2025

Energy stocks in the lead on Thursday; drugmakers weigh on healthcare

Source: MarketWatch

5/8/2025

BeiGene's innovative cancer treatments, Brukinsa and Tevimbra, are driving growth. Click for a look at ONC and its latest earnings results.

Source: SeekingAlpha

5/8/2025

Over the first quarter of 2025, Franklin Global Allocation Fund proved more resilient than its benchmark. Click here to read the full commentary.

Source: SeekingAlpha

5/8/2025

NEW YORK, May 8, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. . ...

Source: Finnhub

5/8/2025

Let’s dig into the relative performance of AbbVie (NYSE:ABBV) and its peers as we unravel the now-completed Q1 therapeutics earnings season.

Source: Yahoo

5/7/2025

We came across a bullish thesis on AbbVie Inc. (ABBV) on Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on ABBV. AbbVie Inc. (ABBV)’s share was trading at $198.47 as of May 2nd. ABBV’s trailing and forward P/E were 84.82 and 16.34 respectively according to Yahoo Finance. AbbVie (ABBV) delivered a strong […]

Source: Yahoo

5/7/2025

Johnson & Johnson and AbbVie are part of the Zacks top Analyst Blog.

Source: Yahoo

5/7/2025

2024 also saw some changes to some of my holdings as the author shuttled several dividend income payers for higher return crypto plays. Click to read.

Source: SeekingAlpha

5/7/2025

No matter how high President Trump cranks up tariffs, many industries are never coming back to the U.S. For industries that require cheap labor such as apparel and toys, bringing that production to Pennsylvania or Ohio just doesn’t make sense. For pharma, an industry in which gross margins are among the highest in the S&P 500, labor was never really the reason for moving offshore to places like Ireland—it was always about playing the global tax game. Tariffs are certainly getting pharma CEOs to listen, and many are already stockpiling imports while expanding production within existing U.S. sites.

Source: Yahoo

5/7/2025

For Q1 2025, the Fidelity Select Health Care Portfolio returned -1.03%, underperforming the MSCI health care index. Click here to read the full commentary.

Source: SeekingAlpha

5/7/2025

AbbVie Inc. (NYSE:ABBV), a biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. If You Bought AbbVie Stock 10 Years Ago The company's stock traded at ...

Source: Yahoo

5/6/2025

Both JNJ and ABBV expect their sales and profits to improve in 2025.

Source: Yahoo

5/6/2025

AbbVie (NYSE: ABBV) will participate in the Bank of America Securities Healthcare Conference on Wednesday, May 14, 2025. Management will participate in a fireside chat at 12:00 p.m. Central time.

Source: Yahoo

5/6/2025

While broader US equity markets were challenged in the first quarter, value stocks posted a small gain. Read more here.

Source: SeekingAlpha

5/6/2025

We recently published a list of ChatGPT Stock Advice: Top 12 Stock Recommendations. In this article, we will take a look at where AbbVie Inc. (NYSE:ABBV) stands against other top stock recommendations by ChatGPT. After a two-year surge of 53%, the stock market has been taken for a wild ride in 2025, driven by uncertainties […]

Source: Yahoo

5/6/2025

For Q1 2025, Fidelity Large Cap Stock Fund returned -2.29%, outpacing the -4.27% result of the benchmark, the S&P 500® index. Click here to read the full commentary.

Source: SeekingAlpha

5/6/2025

Chief executives at the largest drugmakers in the world are confident tariffs and pricing measures won’t be a major problem. But they’re still poised for change.

Source: Yahoo